Cello Health (CLL) Share Price

Best deals to access real time data!
Level 2 Basic Monthly Subscription for only ~~£62.08~~
Silver Monthly Subscription for only ~~£17.37~~
UK/US Silver Monthly Subscription for only £30.59
VAT not included

Stock Name	Stock Symbol	Market	Stock Type	Stock ISIN	Stock Description
Cello Health Plc	CLL	London	Ordinary Share	GB00B0310763	ORD 10P

	Price Change	Price Change %	Stock Price	High Price	Low Price	Open Price	Close Price	Last Trade
	0.00	0.0%	127.50	127.50	127.50	127.50	127.50	08:00:00

more quote information »

Industry Sector
MEDIA

Cello Health CLL Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
21/03/2019	Final	GBX	2.75	31/12/2017	31/12/2018	25/04/2019	26/04/2019	24/05/2019	3.85
19/09/2018	Interim	GBX	1.1	31/12/2017	31/12/2018	04/10/2018	05/10/2018	02/11/2018	0
22/03/2018	Final	GBX	2.45	31/12/2016	31/12/2017	03/05/2018	04/05/2018	25/05/2018	3.5
20/09/2017	Interim	GBX	1.05	31/12/2016	31/12/2017	05/10/2017	06/10/2017	03/11/2017	0
22/03/2017	Final	GBX	2.4	31/12/2015	31/12/2016	04/05/2017	05/05/2017	26/05/2017	3.4
14/09/2016	Interim	GBX	1	31/12/2015	31/12/2016	06/10/2016	07/10/2016	04/11/2016	0
17/03/2016	Final	GBX	2.02	31/12/2014	31/12/2015	05/05/2016	06/05/2016	27/05/2016	2.86
16/09/2015	Interim	GBX	0.84	31/12/2014	31/12/2015	21/10/2015	22/10/2015	27/11/2015	0
19/03/2015	Final	GBX	1.8	31/12/2013	31/12/2014	30/04/2015	01/05/2015	29/05/2015	2.6
17/09/2014	Interim	GBX	0.8	31/12/2013	31/12/2014	01/10/2014	03/10/2014	07/11/2014	0
20/03/2014	Final	GBX	1.61	31/12/2012	31/12/2013	04/06/2014	06/06/2014	04/07/2014	2.25
18/09/2013	Interim	GBX	0.64	31/12/2012	31/12/2013	04/12/2013	06/12/2013	06/01/2014	0
13/03/2013	Final	GBX	1.42	31/12/2011	31/12/2012	29/05/2013	31/05/2013	05/07/2013	2
19/09/2012	Interim	GBX	0.58	31/12/2011	31/12/2012	07/12/2012	09/12/2012	04/01/2013	0
13/03/2012	Final	GBX	1.17	31/12/2010	31/12/2011	06/06/2012	08/06/2012	06/07/2012	1.72
13/09/2011	Interim	GBX	0.55	31/12/2010	31/12/2011	07/12/2011	09/12/2011	06/01/2012	0
15/03/2011	Final	GBX	0.9	31/12/2009	31/12/2010	08/06/2011	10/06/2011	08/07/2011	1.43
14/09/2010	Interim	GBX	0.525	31/12/2009	31/12/2010	06/10/2010	08/10/2010	03/11/2010	0
16/03/2010	Final	GBX	0.8	31/12/2008	31/12/2009	19/05/2010	21/05/2010	16/06/2010	1.3
15/09/2009	Interim	GBX	0.5	30/06/2008	30/06/2009	07/10/2009	09/10/2009	04/11/2009	0
17/03/2009	Final	GBX	0.75	31/12/2007	31/12/2008	20/05/2009	22/05/2009	17/06/2009	1.25
16/09/2008	Interim	GBX	0.5	30/06/2007	30/06/2008	08/10/2008	10/10/2008	05/11/2008	0
23/03/2008	Final	GBX	0.75	31/12/2006	31/12/2007	21/05/2008	23/05/2008	18/06/2008	1.2
20/03/2007	Final	GBX	0.6	31/12/2005	31/12/2006	23/05/2007	25/05/2007	15/06/2007	1
05/09/2006	Interim	GBX	0.4	30/12/2005	30/06/2006	20/09/2006	22/09/2006	13/10/2006	0

Date	Subject
21/3/2019 10:44	davebowler: Cenkos; Organic momentum continues Today’s largely in-line results were well flagged by January’s trading update, but there are notable beats on EPS, DPS and Net cash. The group continues its organically focused delivery, leveraging Signal’s digital capabilities into the healthcare space, alongside new office openings. This will continue Cello’s migration over time into a more healthcare-focused, US-centric and higher margin business. We feel the defensive nature and FCF potential of Cello are not fairly valued in the current share price. Read Full Thread Follow Reply
08/2/2017 09:52	qs99: Continued good moves....a great story really IMO given fund raise, more than required, implying more deals (+use of debt) in future, tech focus in new broker notes, share price already 10%+ above placing price as well received....more to come IMO as reckon from this share price rise, there are a few who are buying into story....DYOR and gla Read Full Thread Follow Reply
06/2/2017 12:06	davebowler: FinnCap; Post the placing, Cello has net cash and, with an acquisition, has signalled its intent to invest for growth now that the VAT issue is firmly behind it. We continue to believe Pulsar, its social media tool, is in the share price for free, but also increasingly that Cello has developed a widening range of technologies that are performing well and support good profit growth potential. Cello is moving away from an ‘hours utilised and billed' type model towards a technology-backed model, a more valuable proposition. Read Full Thread Follow Reply
01/2/2017 11:39	zipstuck: The oversubscribed placing underpins the share price and there is all to play for in 2017 Read Full Thread Follow Reply
19/1/2017 09:36	davebowler: Price: 100.0p Target Price: 132.0p finncap.com Cello has confirmed the Group delivered an encouraging trading performance in 2016 and 2017 begins with good momentum from existing and new clients. Most importantly for our buy case, there has been an ‘excellent performance’ from Cello’s growing suite of software-enabled products. We make no changes to our forecasts and continue to believe the share price significantly undervalues the technologies Cello has developed, most notably Pulsar its social media analytics tool which we believe is in the price for free. Read Full Thread Follow Reply
28/9/2016 09:58	davebowler: Finncap; Price: 106.0p Target Price: 132p Cello has an overlooked and potentially significantly undervalued asset that is now out of development phase. Cello Pulsar is a social media analytics tool that has significant points of difference to the competition. In the right hands, social media data can inform, direct and optimise marketing campaigns but to date its usage has been constrained by early-stage science and customer unfamiliarity. Competitors in this area have individually raised nearly half of Cello's market cap, emphasising Pulsar’s potential to add very material value to the share price. We initiate at Buy. Read Full Thread Follow Reply
03/6/2014 17:44	qs9: nice IMO to see directors taking advantage of recent share price weakness... Read Full Thread Follow Reply
08/5/2013 14:58	hpcg: I think its a bit chicken and egg with regards to liquidity / spread; its thinly traded which puts people off. If they participated then there would be more liquidity! However I'm speculating as to the motives of others, and it could just be that investors want to see more prolonged evidence of progress. If the company does the business the share price will as well. Read Full Thread Follow Reply
17/9/2010 21:17	stegrego: Hybridan Cello Group (CLL 46p/£28.25m) Cello continues its impressive share price performance with a further rise of over 25 per cent since the end of July when we last commented on the Company. Today it announced its half year results showing headline ongoing operating profit up 25 per cent to £3.3m (2009: £2.6m), margins improved to 10.9 per cent (2009: 8.9 per cent) and net debt down to £11.7m (2009: £14.8m). The fall off in income from the public sector has not impacted materially the overall mix of business, with the top 20 clients from 2009 remaining significant revenue generators for the Company in 2010, with many increasing their levels of expenditure. The largest customer accounts for only 4.4 per cent of total income, with the top 20 customers for less than 40 per cent. The robust Pharmaceutical sector on the other hand now accounts for over 25 percent of the group's income. The Company thus appears to have created a secure and solid base from which to advance. On the results the CEO commented "We are now seeing a pick up from our clients in the private sector across a range of industries....(and) have started to carefully organically expand the business again". This positive statement, along with the small 5 percent increase in the interim dividend bodes well for investors who we expect to continue to support the progress of this growing company. Read Full Thread Follow Reply
01/4/2010 12:40	glasshalfull: Well I disagree GCI :-) I've been nibbling away and have bought a few CLL since results which I expect to represent the nadir of the share price underperformance. I had researched and was a holder of CLL back in 2006 and discovered that I still had a few (dormant account), so only recently got up to speed on developments since. My interest was rekindled having carried out comprehensive research on Adventis (ATG) a marketing services company - see link below - and I noticed that both ATG and CLL had failed to enjoy the shareprice recovery that many of their peers had. http://boards.fool.co.uk/Message.asp?mid=11859117 I've started a write-up on CLL and will post when complete. Regards GHF Read Full Thread Follow Reply

Date

Subject

21/3/2019
10:44

davebowler: Cenkos; Organic momentum continues Today’s largely in-line results were well flagged by January’s trading update, but there are notable beats on EPS, DPS and Net cash. The group continues its organically focused delivery, leveraging Signal’s digital capabilities into the healthcare space, alongside new office openings. This will continue Cello’s migration over time into a more healthcare-focused, US-centric and higher margin business. We feel the defensive nature and FCF potential of Cello are not fairly valued in the current share price.

Read Full Thread

08/2/2017
09:52

qs99: Continued good moves....a great story really IMO given fund raise, more than required, implying more deals (+use of debt) in future, tech focus in new broker notes, share price already 10%+ above placing price as well received....more to come IMO as reckon from this share price rise, there are a few who are buying into story....DYOR and gla

Read Full Thread

06/2/2017
12:06

davebowler: FinnCap; Post the placing, Cello has net cash and, with an acquisition, has signalled its intent to invest for growth now that the VAT issue is firmly behind it. We continue to believe Pulsar, its social media tool, is in the share price for free, but also increasingly that Cello has developed a widening range of technologies that are performing well and support good profit growth potential. Cello is moving away from an ‘hours utilised and billed' type model towards a technology-backed model, a more valuable proposition.

Read Full Thread

01/2/2017
11:39